drugset
drugset / Trial / NCT03010423

Efficacy Study of Oral Nicorandil on Improving Microvascular Function in Female Non-obstructive Coronary Artery Disease (CAD) Participants

NCT03010423 ↗

Phase 4 Terminated 8 enrolled Merck KGaA, Darmstadt, Germany Merck Serono Co., Ltd., China · collab
NaSingle-groupOpen-labelTreatment

Summary

The study is a single-center, interventional, pilot study to evaluate the improvement of microvascular function by positron emission tomography (PET) after twelve-week treatment of oral nicorandil in female non-obstructive CAD Participants.

Timeline

Start
2016-11-30
Primary completion
2019-07-09
Completion
2019-07-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Nicorandil Other / unclassified 5 mg Oral

Indications

nonobstructive coronary artery disease